T1	Participants 126 164	A follow-up of 212 randomized patients
T2	Participants 167 241	Two hundred and twelve patients treated for prostatic cancer grade I or II
T3	Participants 298 493	patients were part of a multicentre study in the Stockholm area and had been randomized to treatment with either estramustine phosphate (Estracyt) or polyestradiol phosphate and ethinyl estradiol
